May 14, 2026
LL-37 Cathelicidin Peptide in Preclinical Research
Preclinical research on LL-37 cathelicidin peptide covers membrane disruption, immunomodulation, wound healing, and anti-biofilm activity in lab models.
RESEARCH NOTES
May 14, 2026
Preclinical research on LL-37 cathelicidin peptide covers membrane disruption, immunomodulation, wound healing, and anti-biofilm activity in lab models.
May 14, 2026
Explore SS-31 Elamipretide mitochondrial cardiolipin research: electron transport chain data, ROS reduction, cardiac and renal preclinical model findings.
May 14, 2026
Explore preclinical research on the Humanin mitochondrial peptide: neuroprotection, BAX inhibition, STAT3 signaling, and comparisons with MOTS-c and SS-31.
May 14, 2026
Review preclinical data on DSIP delta sleep peptide: EEG delta wave promotion, circadian entrainment, stress modulation, and antioxidant findings in rodents.
May 14, 2026
Research on PT-141 Bremelanotide melanocortin MC4R receptor binding, CNS signalling, and preclinical rodent model findings reviewed by specialist researchers.
May 14, 2026
Explore preclinical research on AOD-9604 GH fragment: lipolytic mechanisms, adipogenesis inhibition, β3-adrenergic signalling, and safety data in rodent models.
May 14, 2026
Explore preclinical Thymosin Alpha-1 immune research: T-cell maturation, TLR signalling, NK activity, antiviral and antitumour findings in animal models.
May 14, 2026
Explore Hexarelin peptide research — GHSR-1a agonism, CD36 cardiac binding, GH pulse amplitude, and cardioprotection data from preclinical animal models.
May 14, 2026
Explore preclinical GHRP-2 growth hormone research: GHSR-1a agonism, GH pulse amplitude, ghrelin mimicry, and synergy with GHRH analogs in animal models.
May 14, 2026
Explore Ipamorelin GHRP mechanisms, GHSR-1a receptor agonism, selectivity data, and 2022–2025 preclinical research findings in this expert research overview.